Supplemental Figures 13-16 from Synthetic Lethality of PARP Inhibitors in Combination with MYC Blockade Is Independent of BRCA Status in Triple-Negative Breast Cancer

Supplementary Figure 13 Effects of treatment with Dinaciclib and niraparib on TNBC in vivo. Supplementary Figure 14 Niraparib resistance of breast cancer cells. (a-d) Knockdown of 53BP1 expression in HCC1806 cells. Supplementary Figure 15 Analysis of MYC mRNA expression in different TCGA cancer patient cohorts. Supplementary Figure 16 Evaluation of TCGA cohort of 82 patients with TNBC, separated according to MYC expression and showing correlation with HR mutation status. Molecular analysis of the patients' tumors predicted their response to PARPi-targeted therapy.